What is Braftovi used to treat?
Braftovi is used in combination with other drugs to treat patients with advanced melanoma, advanced non-small cell lung cancer and advanced colorectal cancer with BRAF gene mutations.
Braftovi is an oral small molecule BRAF kinase inhibitor.
Melanoma
Braftovi (encorafenib) is used in combination with Mektovi (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.
Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.
Colorectal Cancer
Braftovi is used in combination with Erbitux (cetuximab) for the treatment of adult patients with
metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Braftovi is also used in combination with Erbitux (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for the first-line treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
- This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
BRAF mutations are estimated to occur in up to 15% of people with metastatic colorectal cancer.
Braftovi is not indicated for treatment of patients with wild-type BRAF CRC.
Non-Small Cell Lung Cancer
Braftovi is used in combination with Mektovi (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
BRAF mutations are estimated to occur in 2% to 5% of people with metastatic non-small cell lung cancer.
Braftovi is not indicated for the treatment of patients with wild-type BRAF NSCLC.
Related questions
References
- Braftovi (encorafenib) prescribing information. Revised 12/2024. Pfizer Inc. New York, NY. Accessed Dec 29, 2024 at https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf
Read next
How long does it take for Keytruda to work?
The time it takes for Keytruda to work can vary based on the type and stage of cancer. Typically, a response to treatment becomes apparent within 2-4 months of starting Keytruda. This timeframe is referred to as "time to response," which measures when a patient's cancer begins to show signs of responding to the treatment. You can find the specific "time to response" data from clinical trials in the table below. Continue reading
Pembrolizumab vs. nivolumab: How do they compare?
Pembrolizumab and nivolumab are both prescription medications used to treat various types of cancers, including solid tumors and blood cancers. They may be used alone or in combination with other medicines for cancers that are more advanced, have spread in the body, or are no longer responding to previous treatments. Continue reading
How long does oxaliplatin stay in your system?
Oxaliplatin (Eloxatin) is a platinum-based drug used to treat colon cancer which is administered by intravenous (IV) infusion. After it is administered, oxaliplatin is converted into total platinum, ultrafilterable (free) platinum and erythrocyte platinum.
Ultrafiterable platinum represents the main active substance that provides oxaliplatin’s anti-cancer and toxic properties. Initially plasma ultrafiltrate is distributed quite quickly in the body in two phases, with half-lives (the amount of time it takes to reduce by half) of 0.43 and 16.8 hours, respectively, as the drug is moved into tissues and also cleared by the kidneys.
The third phase of elimination (the terminal half-life of platinum in ultrafiltrate), however, can be as long as 392 hours (approx. 16 days), although this is thought to reflect clearance of mostly inactive platinum conjugates.
After a single oxaliplatin infusion, about 54 percent of the drug is excreted in urine within 5 days. Continue reading
Related medical questions
- Why do you need to take Xeloda with food?
- How many cycles of oxaliplatin can you have?
- How effective is Lumakras, what's the survival rate?
- What is the difference between Mvasi and Avastin?
- How long does Lonsurf increase survival in colorectal cancer?
- Opdivo vs Opdivo Qvantig: What is the Difference?
- How effective are Opdivo and Yervoy when taken together?
- How effective is tucatinib (Tukysa) for breast cancer?
- What's the mechanism of action for tucatinib?
- Common Types of Cancer Medications
- What type of cancer is Tecentriq used to treat?
- What is the difference between Opdivo and Keytruda?
- What happens when you stop taking Opdivo for melanoma?
- Are there cost-saving programs for Tecentriq?
- How effective is atezolizumab (Tecentriq)?
- Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?
- Does atezolizumab (Tecentriq) cause hair loss?
- How is atezolizumab (Tecentriq) administered?
- Sunscreen Safety: What do you need to know?
Drug information
Related support groups
- Encorafenib (2 questions, 3 members)
- Braftovi (2 questions, 3 members)
- Colorectal Cancer (19 questions, 53 members)
- Melanoma (20 questions, 52 members)
- Skin Cancer (13 questions, 38 members)
- Melanoma - Metastatic (7 questions, 30 members)